ImmuPharma PLC (IMM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImmuPharma PLC (IMM) has a cash flow conversion efficiency ratio of -2.979x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.00 Million ≈ $-122.04 USD) by net assets (GBX336.70K ≈ $40.97 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ImmuPharma PLC (IMM) liquidity interval to measure how many days the company can operate on defensive assets alone.
ImmuPharma PLC - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how ImmuPharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ImmuPharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmuPharma PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greiffenberger AG
F:GRF
|
0.089x |
|
Baltic Bridge S.A.
WAR:WIS
|
N/A |
|
Kendrick Resources PLC
LSE:KEN
|
-0.071x |
|
Virpax Pharmaceuticals Inc
NASDAQ:VRPX
|
3.142x |
|
Water Ways Technologies Inc
V:WWT
|
0.002x |
|
VATIC VENTURES CORP.
F:V8V
|
0.002x |
|
Alchimie Sa
PA:ALCHI
|
0.739x |
|
EGR EXPL LTD
F:Z0R
|
-0.091x |
Annual Cash Flow Conversion Efficiency for ImmuPharma PLC (2004–2024)
The table below shows the annual cash flow conversion efficiency of ImmuPharma PLC from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see IMM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-542.86K ≈ $-66.05 |
GBX-1.77 Million ≈ $-215.25 |
3.259x | +352.29% |
| 2023-12-31 | GBX1.06 Million ≈ $128.52 |
GBX-1.36 Million ≈ $-166.01 |
-1.292x | -38.87% |
| 2022-12-31 | GBX2.52 Million ≈ $307.02 |
GBX-2.35 Million ≈ $-285.57 |
-0.930x | +15.06% |
| 2021-12-31 | GBX4.41 Million ≈ $536.99 |
GBX-4.83 Million ≈ $-588.06 |
-1.095x | -217.56% |
| 2020-12-31 | GBX9.65 Million ≈ $1.17K |
GBX-3.33 Million ≈ $-405.09 |
-0.345x | +56.96% |
| 2019-12-31 | GBX5.27 Million ≈ $641.11 |
GBX-4.22 Million ≈ $-513.62 |
-0.801x | -29.36% |
| 2018-12-31 | GBX7.62 Million ≈ $927.50 |
GBX-4.72 Million ≈ $-574.43 |
-0.619x | +49.93% |
| 2017-12-31 | GBX3.57 Million ≈ $434.91 |
GBX-4.42 Million ≈ $-537.91 |
-1.237x | -5.76% |
| 2016-12-31 | GBX5.55 Million ≈ $674.79 |
GBX-6.49 Million ≈ $-789.17 |
-1.170x | +52.34% |
| 2015-12-31 | GBX1.69 Million ≈ $205.67 |
GBX-4.15 Million ≈ $-504.74 |
-2.454x | -462.18% |
| 2014-12-31 | GBX5.71 Million ≈ $694.18 |
GBX-2.49 Million ≈ $-303.03 |
-0.437x | +39.73% |
| 2013-12-31 | GBX5.40 Million ≈ $657.48 |
GBX-3.91 Million ≈ $-476.20 |
-0.724x | -87.19% |
| 2012-12-31 | GBX8.42 Million ≈ $1.02K |
GBX-3.26 Million ≈ $-396.30 |
-0.387x | -43.72% |
| 2011-12-31 | GBX12.51 Million ≈ $1.52K |
GBX-3.37 Million ≈ $-409.67 |
-0.269x | +37.19% |
| 2010-12-31 | GBX15.97 Million ≈ $1.94K |
GBX-6.84 Million ≈ $-832.84 |
-0.429x | -164.78% |
| 2009-12-31 | GBX18.08 Million ≈ $2.20K |
GBX11.96 Million ≈ $1.46K |
0.662x | +389.02% |
| 2008-12-31 | GBX11.24 Million ≈ $1.37K |
GBX-2.57 Million ≈ $-313.06 |
-0.229x | +80.78% |
| 2007-12-31 | GBX3.05 Million ≈ $371.10 |
GBX-3.63 Million ≈ $-441.91 |
-1.191x | -239.23% |
| 2006-03-31 | GBX2.50 Million ≈ $304.66 |
GBX-879.00K ≈ $-106.95 |
-0.351x | -1391.04% |
| 2005-03-31 | GBX993.00K ≈ $120.82 |
GBX27.00K ≈ $3.29 |
0.027x | +2559.21% |
| 2004-03-31 | GBX978.00K ≈ $118.99 |
GBX1.00K ≈ $0.12 |
0.001x | -- |
About ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more